Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: Case report and review of the literature

Pharmacotherapy

Volumn 30, Issue 3, 2010, Pages

  Myzienski, April E ^a   Lutz, Mark F ^a,b   Smythe, Maureen A ^a,b  

^a BEAUMONT HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Heparin dosing; Obesity; PE; Pulmonary embolism; Venous thromboembolism; VTE

Indexed keywords

FONDAPARINUX; HEPARIN; ANTICOAGULANT AGENT;

ADULT; ANAMNESIS; ARTICLE; BODY WEIGHT; BOLUS INJECTION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER FLOWMETRY; DRUG WITHDRAWAL; ELECTRIC ACTIVITY; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HUMAN; HYPOXEMIA; INFUSION RATE; LUNG EMBOLISM; MALE; OBESITY; PARTIAL THROMBOPLASTIN TIME; TRANSTHORACIC ECHOCARDIOGRAPHY; VENOUS THROMBOEMBOLISM; VITAL SIGN; DOSE CALCULATION; FATALITY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MORBID OBESITY; REVIEW;

ADULT; ANTICOAGULANTS; BODY WEIGHT; DRUG DOSAGE CALCULATIONS; FATAL OUTCOME; FEMALE; HEPARIN; HUMANS; IDEAL BODY WEIGHT; INFUSIONS, INTRAVENOUS; MALE; OBESITY; OBESITY, MORBID; PULMONARY EMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 77649216583     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.3.324     Document Type: Article

References (22)

1. Smythe MA, Koerber J. Heparin monitoring: the confusion continues. Pharmacotherapy 1999;19(11):1240-2.
2. Raschke RA, Reily BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a standard care nomogram: a randomized controlled trial. Ann Intern Med 1993;119:874-81.
3. Bernardi E, Piccioli A, Oliboni G, Zuin R, Girolami A, Prandoni P. Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism - an overview. Thromb Haemost 2000;84(1):22-6.
4. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low molecular weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009;43(6):1064-83.
5. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines, 8th ed. Chest 2008;133(6 suppl):141S-59.
6. Schaefer DC, Hufnagle J, Williams L. Rapid heparin anticoagulation: use of a weight-based nomogram, Am Fam Physician 1996;54:2517-21.
7. Centers for Disease Control and Prevention. Overweight and obesity. U.S. obesity trends: trends by state 1985-2008. Available from www.cdc.gov/nccdphp/dnpa/obesity/trend/maps. Accessed July 28, 2009.
8. The Joint Commission. Accreditation program: hospital national patient safety goals. NPSG.03.05.01. Reduce the likelihood of patient harm associated with the use of anticoagulant therapy. Available from http://www.jointcommission.org/NR/rdonlyres/868C9E07-037F-433D-8858- 0D5FAA4322F2/0/RevisedChapter-HAP-NPSG-20090924.pdf. Accessed January 5, 2010.
9. The Joint Commission. Preventing errors relating to commonly used anticoagulants. Sentinel event alert #41, September 4, 2008. Available from http://www.jointcommission.org/ SentinelEvents/SentinelEventAlert/sea-41.htm. Accessed July 28, 2009.
10. Institute for Safe Medication Practices. Anticoagulant safety takes center stage in 2007. ISMP medication safety alert, January 11, 2007;12(1):1-3.
11. Barletta JF, DeYoung JL, McAllen K, Baker R, Pendleton, K. Limitations of a standardized weight-based nomogram for heparin dosing in patients with morbid obesity. Surg Obes Relat Dis 2008;4:748-53.
12. Ellison MJ, Sawyer WT, Mills TC. Calculation of heparin dosage in a morbidly obese woman. Clin Pharm 1989;8:65-8.
13. Holliday DM, Watling SM, Yanos J. Heparin dosing in the morbidly obese patient. Ann Pharmacother 1994;28:1110-11.
14. Dee BM, Thomas ML. Safety and efficacy of a high-intensity, weight-based, intravenous heparin protocol revision in patients who are obese. Hosp Pharm 2008;43(11):895-902.
15. Spruill WJ, Wade EW, Huckaby WG, Leslie RB. Achievement of anticoagulation by using a weight-based heparin dosing protocol for obese and non-obese patients. Am J Health Syst Pharm 2001;58:2143-6.
16. Yee WP, Norton LL. Optimal weight base for a weight-based heparin dosing protocol. Am J Health Syst Pharm 1998;55:159-62.
17. Schwiescow S, Wessell A, Steyer TE. Use of a modified dosing weight for heparin therapy in a morbidly obese patient. Ann Pharmacother 2005;39:753-6.
18. Khan SU, Groth ML, Hurewitz AN. Optimal dosing of unfractionated heparin in obese patients with venous thromboembolism. Chest 2005;128(4):406S-7.
19. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva: World Health Organization, 1998.
20. Owens TM. Bariatric surgery risks, benefits and care of the morbidly obese. Nurse Clin North Am 2006;41(2):249-63, vi.
21. Douma RA, Gibson NS, Gerdes VE, et al. Validity and clinical utility of the simplified Wells rule for assessing clinical probability for the exclusion of pulmonary embolism. Thromb Haemost 2009;101(1):197-200.
22. Hull RD, Raskob GE, Jay RM, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315(18):1109-14.